ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 255 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,803,536 | -28.6% | 104,337 | -5.2% | 0.00% | 0.0% |
| Q2 2023 | $3,924,384 | +46.3% | 110,050 | +4.2% | 0.00% | 0.0% |
| Q1 2023 | $2,683,154 | -57.4% | 105,636 | -32.0% | 0.00% | -50.0% |
| Q4 2022 | $6,301,118 | +17.6% | 155,353 | -4.2% | 0.00% | 0.0% |
| Q3 2022 | $5,360,000 | +0.9% | 162,171 | +7.5% | 0.00% | 0.0% |
| Q2 2022 | $5,311,000 | -40.2% | 150,808 | -22.0% | 0.00% | 0.0% |
| Q1 2022 | $8,888,000 | -37.2% | 193,271 | -9.5% | 0.00% | -50.0% |
| Q4 2021 | $14,154,000 | +5.2% | 213,489 | -0.9% | 0.00% | +33.3% |
| Q3 2021 | $13,454,000 | -27.9% | 215,512 | -4.3% | 0.00% | -25.0% |
| Q2 2021 | $18,650,000 | +11.3% | 225,192 | -10.9% | 0.00% | 0.0% |
| Q1 2021 | $16,752,000 | -18.2% | 252,640 | -5.3% | 0.00% | -20.0% |
| Q4 2020 | $20,475,000 | +101.6% | 266,840 | +13.1% | 0.01% | +66.7% |
| Q3 2020 | $10,158,000 | -9.7% | 235,895 | -9.4% | 0.00% | 0.0% |
| Q2 2020 | $11,251,000 | +72.3% | 260,480 | +14.8% | 0.00% | +50.0% |
| Q1 2020 | $6,529,000 | -56.1% | 226,937 | -3.1% | 0.00% | -50.0% |
| Q4 2019 | $14,857,000 | +126.9% | 234,225 | +0.8% | 0.00% | +100.0% |
| Q3 2019 | $6,548,000 | +8.3% | 232,322 | +1.8% | 0.00% | 0.0% |
| Q2 2019 | $6,045,000 | +28.0% | 228,122 | -11.3% | 0.00% | +100.0% |
| Q1 2019 | $4,721,000 | +51.6% | 257,287 | +2.6% | 0.00% | 0.0% |
| Q4 2018 | $3,115,000 | +31.4% | 250,790 | +102.8% | 0.00% | 0.0% |
| Q3 2018 | $2,370,000 | +37.5% | 123,682 | -2.4% | 0.00% | 0.0% |
| Q2 2018 | $1,724,000 | +219.9% | 126,779 | +69.8% | 0.00% | – |
| Q1 2018 | $539,000 | +109.7% | 74,678 | +6.7% | 0.00% | – |
| Q4 2017 | $257,000 | +188.8% | 69,997 | +237.3% | 0.00% | – |
| Q3 2017 | $89,000 | +140.5% | 20,751 | -9.0% | 0.00% | – |
| Q2 2017 | $37,000 | -86.7% | 22,801 | -84.8% | 0.00% | – |
| Q1 2017 | $278,000 | +192.6% | 150,346 | +144.8% | 0.00% | – |
| Q4 2016 | $95,000 | -87.4% | 61,413 | -40.2% | 0.00% | – |
| Q3 2016 | $754,000 | +20.3% | 102,631 | -12.9% | 0.00% | – |
| Q2 2016 | $627,000 | – | 117,842 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,346 | $62,945,000 | 41.38% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $250,206,000 | 32.27% |
| Aquilo Capital Management, LLC | 365,926 | $28,078,000 | 5.84% |
| L1 Capital Pty Ltd | 298,687 | $23,127,000 | 4.32% |
| First Light Asset Management, LLC | 704,449 | $54,052,000 | 4.00% |
| ACUTA CAPITAL PARTNERS, LLC | 139,000 | $10,665,000 | 2.90% |
| Evolutionary Tree Capital Management, LLC | 48,265 | $3,703,000 | 2.82% |
| Parkman Healthcare Partners LLC | 127,171 | $9,758,000 | 2.50% |
| Capital Impact Advisors, LLC | 88,183 | $6,766,000 | 1.66% |
| Tri Locum Partners LP | 56,003 | $4,297,000 | 1.56% |